
Alice B Gottlieb MD PhD
Clinical Professor of Dermatology, Icahn School of Medicine at Mount Sinai; Medical Director of the Dermatology Department at Beth Israel Hospital, NY, NY
Join to view full profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-648-3392
Fax+1 214-648-5553
Dr. Gottlieb is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Dermatology, 1990 - 1993
New York Presbyterian Hospital (Cornell Campus)Fellowship, Rheumatology, 1982 - 1984
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1980 - 1982
Weill Cornell MedicineClass of 1980
Rockefeller UniversityPh.D., Immunology, 1979
Certifications & Licensure
NY State Medical License 1981 - 2028
TX State Medical License 2025 - 2027
CT State Medical License 1988 - 2024
MA State Medical License 2006 - 2018
NJ State Medical License 1995 - 2011
American Board of Dermatology Dermatology
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification eClinicalWorks, eClinicalWorks, LLC, 2013-2014, 2016
- CMS Meaningful Use Stage 1 Certification eClinicalWorks, eClinicalWorks, LLC, 2013-2014, 2016
Publications & Presentations
PubMed
- Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Resul...Alexis Ogdie, Joseph F Merola, Philip J Mease, Christopher T Ritchlin, Jose U Scher
Arthritis & Rheumatology. 2026-08-01 - Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.Philip J Mease, Vinod Chandran, April W Armstrong, Ricardo Blanco, Alexis Ogdie
Arthritis & Rheumatology. 2026-07-20 - Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting.Dafna D Gladman, Wilson Bautista-Molano, Denis Poddubnyy, William Tillett, Maarten de Wit
The Journal of Rheumatology. 2026-07-07
Press Mentions
Expert Shares PsA Screening Tips for People with PsoriasisNovember 9th, 2025
Generalized Pustular Psoriasis Linked to Higher Mortality Risk Than Plaque Psoriasis: StudyJuly 13th, 2025
JDD in the News: Benefits of Long-Term Ixekizumab in Psoriasis; Secukinumab in Psoriasis Patients with Skin of ColorSeptember 19th, 2024
Grant Support
- Immunological Mechanisms In PsoriasisNational Center For Research Resources1988–1990
- Monoclonal Probes Of Epidermal DifferentiationNational Center For Research Resources1987
Professional Memberships
- Fellow
- Fellow
External Links
- YouTubehttps://www.youtube.com/embed/6kXBz5wHoJ8
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









